Merck & Co., Inc. (MRK)[Tv]

Key Events

• FDA approval of Lipfendra (enlicitide), Merck’s first oral PCSK9 inhibitor, marks a transformative milestone in cardiovascular medicine and represents a strategic pivot away from oncology dependency, positioning Merck for a high-margin, first-in-class franchise with blockbuster potential.
• Merck reported a Q2 2026 earnings miss with a $1.3 billion GAAP net loss and a $0.13 EPS shortfall, driven by a $2.31 per share one-time charge from the Terns Pharmaceuticals acquisition, triggering a major downward revision of full-year non-GAAP EPS guidance to $2.66–$2.76.
• Lupin’s FDA-approved launch of a generic version of Sugammadex Injection (Bridion) directly undermines Merck’s monopoly on this high-margin specialty drug, signaling a severe threat to pricing power and profitability in a niche but critical therapeutic segment.
• The failure of the Phase 3 trial for pemigatinib in advanced bladder cancer highlights systemic pipeline execution risks, casting doubt on Merck’s ability to deliver next-generation blockbusters post-2028 Keytruda patent expiration.
• The complete absence of milestone payments from AstraZeneca for Lynparza, despite clinical momentum in new indications, reveals a fundamental breakdown in the value of one of Merck’s most high-profile partnerships and raises serious concerns about its collaboration model.